SiSaf Ltd Appoints Former Oxford BioMedica Executive
SiSaf Ltd Appoints Former Oxford BioMedica Executive, Dr Spiros Servos PhD, MBA as Head of Business Development.
London UK, Dec. 20, 2019 – SiSaf Ltd, pioneers of Bio-Courier® technology, today announced the appointment of Dr Spiros Servos as Head of Business Development. Dr Servos is responsible for maximizing the commercial and strategic value of SiSaf breakthrough non-viral Gene Therapy and New Therapeutic Entity pipeline as well as identifying the most valuable future applications for its unique platform technology.
“With over 20 years’ experience in precision medicine, Dr Servos brings a wealth of knowledge and industry connections to SiSaf” said Dr Suzanne Saffie-Seibert PhD, Founder and CEO of SiSaf. “Spiros has orchestrated some of the landmark deals in the Gene Therapy space and will be invaluable to accelerating the value and application of our Bio-Courier® platform”.
“Throughout my career I have been passionate about developing commercial strategies to ensure patient access to affordable transformational therapies” said Spiros Servos. “SiSaf’s Bio-Courier® technology platform is an elegant solution to one of the thorniest problems facing the industry; the safe and efficient delivery of gene therapeutics to target. I am thrilled to be a part of such an innovative company and excited to help the precision medicine ecosystem embrace SiSaf and unleash the potential of the Bio-Courier® platform.
Dr Servos joins SiSaf from a 5-year tenure with Oxford BioMedica, where he most recently served as the Director of Business Development and Market Access. In that role, he was responsible for managing and supporting the commercialization of their leading Gene Therapy portfolio. In addition, Dr Servos was responsible for assessing price reimbursement potential of Parkinson’s disease assets based on the HTA methodology and cost utility framework as used by NICE and ICER institute. This work was published in the journal of Market Access & Health policy (JMA&HP V6, Issue 1, Aug 2018).
SiSaf are pioneers of silicon-based Bio-Courier® technology that leverages the unique properties of elemental silicon (14Si) to overcome the limitations of current drug technologies. Built upon a decade of research and patented technological innovation, SiSaf’s platform is changing the way therapeutic molecules target disease helping to make tomorrow’s precision medicines a reality. SiSaf is a commercial stage biopharmaceutical company headquartered in Guilford, UK, with fully integrated state-of-the-art research labs, manufacturing and bio-analytical facilities to fast track development. To learn more, please visit www.sisaf.com
About Bio-Courier® Technology
SiSaf’s first-to-market Bio-Courier platform technology leverages the unique properties of bioabsorbable silicon, lipids and amino acids to address the significant challenges of stability, solubility, targeting and controlled release of complex therapeutic molecules.
Its customizable design and fabrication provide unparalleled flexibility with respect to therapeutic molecule type and target cell location. Bio-Couriers degrade to the bioavailable form of silicon, eliminating the accumulation of potentially toxic or immune-activating material and supporting cell health. Cost-effective, scaled manufacturing provides unequalled capacity to address both rare diseases and large patient populations.